An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy [0.03%]
利奈唑胺治疗耐甲氧西林金黄色葡萄球菌(MRSA)的循证评价：临床地位分析
Richard R Watkins,Tracy L Lemonovich,Thomas M File Jr
Richard R Watkins
Methicillin-resistant Staphylococcus aureus (MRSA), including community-associated and hospital-associated strains, is a major cause of human morbidity and mortality. Treatment options have become limited due to the emergence of MRSA strain...
Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide [0.03%]
聚乙二醇卡巴䂥啶缓释片(Polifeprosan 20)在胶质瘤治疗中的作用：替莫唑胺时代下的证据支持
Lawrence Kleinberg
Lawrence Kleinberg
The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine which slowly degrades to release carmustine and protects it from exposure to w...
An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II [0.03%]
赫尔普特(angioedema)I型和II型急性发作治疗中醋氮amide潜在作用的循证评价
Bernard Floccard,Etienne Hautin,Laurence Bouillet et al.
Bernard Floccard et al.
Introduction: Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. ...
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma [0.03%]
瑞道肽姆治疗EGFR变异III阳性胶质母细胞瘤的潜在疗效的循证回顾
Ranjith Babu,D Cory Adamson
Ranjith Babu
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and is universally fatal. Despite surgical resection, radiotherapy, and systemic chemotherapy, the median overall survival is less than 15 months. As current the...
Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency [0.03%]
胰酶：基于证据的评价及其用于治疗胰腺外分泌不足的有效性及安全性的评审
Kei Nakajima,Haruki Oshida,Toshitaka Muneyuki et al.
Kei Nakajima et al.
Pancreatic exocrine insufficiency (PEI) is often observed in patients with pancreatic diseases, including chronic pancreatitis, cystic fibrosis, and tumors, or after surgical resection. PEI often results in malnutrition, weight loss and ste...
Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action [0.03%]
colesevelam氢氯化物：其在治疗高胆固醇血症和二型糖尿病中的应用证据及其作用机制分析
Michael James Zema
Michael James Zema
Colesevelam hydrochloride is a molecularly engineered, second-generation bile acid sequestrant demonstrating enhanced specificity for bile acids which has been approved for use as adjunctive therapy to diet and exercise as monotherapy or in...
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation [0.03%]
阿哌沙班的循证评价及其在房颤患者卒中预防中的潜在价值分析
Prakash Deedwania,Grace W Huang
Prakash Deedwania
Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It is associated with cardioembolic complications, particularly strokes, resulting in severe functional deficit or death. AF patients are first s...
Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation [0.03%]
利那洛肽治疗肠易激综合征和慢性便秘的疗效及安全性证据
Noel Lee,Arnold Wald
Noel Lee
Both irritable bowel syndrome (IBS), characterized by chronic and recurrent abdominal pain and altered bowel habits, and functional constipation are highly prevalent gastrointestinal problems for which many patients seek medical advice. A d...
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia [0.03%]
米波默森治疗同型和严重杂合子家族性高胆固醇血症潜质的循证评价
Klaus G Parhofer
Klaus G Parhofer
Familial hypercholesterolemia (FH) is an autosomal-dominant inherited disease with a prevalence of one in 500 (heterozygous) to one in 1,000,000 (homozygous). Mutations of the low-density lipoprotein (LDL) receptor gene, the apolipoprotein ...
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes [0.03%]
达格列净：2型糖尿病治疗潜力的循证综述
Edward C Chao
Edward C Chao
Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the urine (glucosuria) has transformed what was once solely regarded as an a...